WVU Tech hosts regional math field day
BECKLEY, WV (WVNS) – School students of all different ages gathered at WVU Tech to compete in regional Math Field Day.
These students represented schools from regions 1 and 4 in West Virginia. The competition encompassed many different areas of math, with one being physical estimation.
A Hero McDowell County is lucky to have: Sharon Sagety is a #RemarkableWoman
Jo Frost is the region 1 coordinator for Regional Math Field Day. She told 59News how these math field days help students prepare for their future careers.
'They get to come to the university campus. We start at WVU Tech, then [for states] they will be at West Virginia State University, and [for] national math field day [it will be] at Penn State, so they get to see where they are going, presumably with their education advancement. Penn State is not taking everybody from West Virginia, so it is a great opportunity to see that,' said Frost.
West Virginia State University is the site of the next math field day for the winners from regionals.
Last year, students from Raleigh County made it all the way to nationals, where they and Frost enjoyed an educational experience on the national education scene.
Region 1 featured students from Raleigh, Mercer, McDowell, Monroe, Summers, and Wyoming counties.
Region 4 included students from Fayette, Braxton, Greenbrier, Nicholas, Pocahontas, and Webster counties.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 hours ago
- Yahoo
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024. Media Contact Company Name: Frost & SullivanWebsite: PR@ To view the source version of this press release, please visit Sign in to access your portfolio
Boston Globe
5 days ago
- Boston Globe
What is Fusarium graminearum, the fungus US authorities say was smuggled in from China?
Advertisement Toxic plant pathogens that a Chinese scientist entered the US last year stashed in his backpack. Uncredited/Associated Press What is Fusarium head blight? Fusarium graminearum causes a disease called Fusarium head blight that can wipe out cereal crops such as wheat, barley and maize and rice — it inflicts $1 billion in losses annually on U.S. wheat and barley crops, according to the U.S. Department of Agriculture. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up It isn't the only fungus to cause Fusarium head blight, but it's the most common culprit in the U.S. The fungus infects plants early in the growing season, shriveling wheat grains and blanching crop heads a whitish-tan color. It also causes a toxin to accumulate in wheat kernels that can make them unsafe for people and livestock to eat. Nicknamed 'vomitoxin' because it's most known for causing livestock to throw up, it can also cause diarrhea, abdominal pain, headache and fever in animals and people. Advertisement Wheat and other grain crops are screened for various toxins, including Fusarium graminearum, before they can be used to feed animals and humans. Farmers have to throw out any infected grains, which can cause devastating losses. 'It's one of the many problems that farmers have to deal with that risks their livelihood,' said David Geiser, a Fusarium expert at Penn State. A colonization of Fusarium head blight, a costly fungal disease, growing on field-grown hemp in Kentucky on Sept. 29, 2020. Uncredited/Associated Press What are the accusations? Although Jian and Liu are accused of smuggling Fusarium graminearum into the country, the fungus is already prevalent in the U.S. — particularly in the east and Upper Midwest — and scientists have been studying it for decades. Researchers often bring foreign plants, animals and even strains of fungi to the U.S. to study them, but they must file certain permits before moving anything across state or national borders. Studying the genes of a foreign fungus strain, for example, can help scientists learn how it tolerates heat, resists pesticides or mutates. 'We look at variations among individuals just like we do humans,' said Nicole Gauthier, a plant pathologist at the University of Kentucky who studies Fusarium. That said, it's unclear why the Chinese researchers might have wanted to bring that strain of Fusarium graminearum into the U.S. and why they didn't fill out the proper paperwork to do so.
Yahoo
5 days ago
- Yahoo
NobleAI Introduces Powerful, Practical AI Solutions For Chemistry and Energy
NobleAI's powerful yet easy-to-use VIP Platform and data-efficient, private SBAI models solve real-world problems and accelerate innovation from months to minutes VIP (Visualizations, Insights & Predictions) Platform NobleAI SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- NobleAI announced today commercial availability of its best-in-class VIP (Visualizations, Insights & Predictions) Platform, an enterprise-grade SaaS offering that delivers the richest feature-set in the rapidly-growing materials informatics sector. For chemistry, the VIP Platform dramatically speeds up the development of molecules, compounds, and formulations while reducing the cost and waste associated with the current slow, iterative, lab-centric paradigm. Energy companies use NobleAI's solutions to enhance forecasting accuracy, improve asset performance and reduce operational uncertainty. In both sectors, the result is faster time to market, better technical decisions, and greater profitability. NobleAI also announced the availability of two new pre-built applications that run on the VIP Platform. Deploy Your Own Models (DYOM) and Model Builder For Formulation (MBFF) are industry-first capabilities that democratize access to advanced predictive modeling technology, making powerful practical AI tools accessible across any enterprise. These two new applications join the previously released Risk Assessment and Ingredient Replacement (RAIR) applications in the expanding VIP Platform ecosystem. 'Innovation in chemistry and energy has been constrained by slow and expensive development cycles, even as digital transformation has reshaped other sectors,' said NobleAI CEO Sunil Sanghavi. 'NobleAI's VIP Platform and Science-Based AI technology transform that paradigm fundamentally. We help companies develop and deploy solutions for their real-world problems, whether molecules or oil wells or anything in between. And we do this with unmatched speed, as companies can now do on laptops what previously had to be done in labs, and can achieve results in minutes or days, not months or years. Our practical AI solutions reduce risk and deliver increased revenues and profits for our enterprise customers.' "This is a seminal year for the fusion of AI and science. NobleAI is redefining possibilities by transforming innovation through intelligent, iterative design across industries from chemicals to energy and materials," said Sudeep Basu, PhD, Global Innovation Practice Leader, Frost & Sullivan. VIP Platform: Transformational Capabilities The VIP Platform is an integrated suite of tools for creating and using AI models to solve complex challenges in chemistry, materials and energy. It is the only solution on the market delivering science-based ensemble models, incorporating multiple use case-relevant scales (from molecular to meso to macro) as well as all appropriate scientific principles. This architecture, the core of NobleAI's proprietary SBAI technology, delivers high-confidence predictions even with limited training data. All customer data is strictly private and used only for that customer's model. The VIP Platform enables development teams to generate predictions by conducting rapid virtual, 'in-silico' experiments - including forward and inverse design, and systematically varying ingredient volume or concentrations to test performance impacts (parameter sweeps) - before testing a few promising candidates in the lab, dramatically accelerating the development process. Scientists can check the predictions through explainable AI models, trace predictions back to their scientific foundations, and examine outcomes at any level of detail - eliminating the "black box" problem of today's AI solutions. Other core capabilities of the platform include visualizations and insights. These enable users to explore, compare, and understand model predictions through intuitive, interactive visuals. Teams can analyze prediction uncertainty, generate custom charts and graphs, and compare results side by side to identify trends and optimize outcomes. Interactive side-by-side chart analysis tools, along with suggested experiments for validation, help users interpret AI results quickly and confidently -- turning predictions into actionable insights. VIP is a modern, full-stack platform built with enterprise-grade security and flexible cloud deployment options. VIP Applications: Democratizing AINobleAI is also introducing two powerful, no-code applications on the scalable VIP Platform that democratize access to AI across the enterprise: Deploy Your Own Models (DYOM) enables data science teams to securely integrate and deploy their own proprietary AI models on the VIP Platform. Lab scientists and other users can then run these models on their own and access the full set of rich capabilities of the VIP Platform. Data science teams are freed to focus on model development and improvement. Model Builder For Formulations (MBFF) is a transformational application that puts advanced science-based model creation directly in the hands of product developers and formulators without requiring data science expertise. Through an intuitive, easy-to-use interface, users can upload any available data, define inputs and outputs, and select preferred performance metrics. MBFF validates data quality and generates candidate SBAI models using NobleAI's proprietary technology. Users can select and deploy the most appropriate model directly within the VIP Platform. With the launch of the VIP Platform and its growing suite of applications, NobleAI is transforming how chemistry and energy companies apply practical AI to real-world challenges. NobleAI delivers unmatched speed, scientific rigor and commercial impact — transforming how innovation happens. About NobleAINobleAI delivers practical AI solutions for complex challenges in chemistry and energy. Our data-efficient Science-Based AI (SBAI) technology combines with the powerful Visualizations, Insights & Predictions (VIP) Platform, and enables customers to compress months of work into minutes. Our commercially proven solutions, built on secure, enterprise-ready technology, are trusted by global enterprises to drive innovation, build market share and improve profitability across a wide range of challenges. NobleAI is supported by investments from world-class organizations such as Microsoft, Chevron and Syensqo. For more information about NobleAI, SBAI and the VIP platform, please visit Photos accompanying this announcement are available at: A video accompanying this announcement is available at: CONTACT: Media Contact Laurie Gibson, Kickstart Consulting (650) 815-1438 / gibson@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
